spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  OCD 

 HSMN NewsFeed - 24 Mar 2025
Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease
Devices Neurology Regulatory
 HSMN NewsFeed - 3 Nov 2022
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 27 Jun 2022
Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Sep 2021
Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
Diagnostics Product Launch
 HSMN NewsFeed - 28 Apr 2021
MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms
Devices Neurology Regulatory
 HSMN NewsFeed - 13 Apr 2021
Ortho's VITROS(R) SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media
Diagnostics Regulatory
 HSMN NewsFeed - 17 Mar 2021
MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation
Devices Neurology Product Launch
 HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 11 Aug 2020
MagVenture receives FDA clearance for OCD
Devices Neurology FDA
 HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 17 Aug 2018
FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder
Devices Neurology FDA
 HSMN NewsFeed - 21 Dec 2017
Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Jun 2017
Venus Medtech Acquires U.S. Company InterValve to Create a Systematic TAVR Treatment and Strengthen Global Expansion
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2015
Mazor Robotics Renaissance(R) Guidance System Helping Patients with OCD
Devices Neurosurgery
 HSMN NewsFeed - 23 Feb 2015
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi(R) and Harvoni(R) in India
Biopharmaceuticals Distribution
 HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2014
The Carlyle Group Agrees to Acquire Johnson & Johnson’s Ortho-Clinical Diagnostics for $4.15 Billion
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 1 Aug 2013
First U.S. Cases Using KARL STORZ RECON Diamond TwInS Instruments for Ankle Surgery
Devices Orthopaedic
 HSMN NewsFeed - 1 Nov 2010
Ortho Clinical Diagnostics Receives FDA Clearance for Intact Parathyroid Hormone Assay
Diagnostics FDA
 HSMN NewsFeed - 16 Sep 2010
Medtronic Receives European CE Mark Approval for Deep Brain Stimulation Therapy for Refractory Epilepsy
Devices Neurology Regulatory
 HSMN NewsFeed - 19 Feb 2009
Medtronic Receives FDA HDE Approval to Commercialize the First Deep Brain Stimulation (DBS) Therapy for a Psychiatric Indication in the United States
Devices Neurology
 HSMN NewsFeed - 28 Apr 2008
Clinical Data on the Use of Medtronic's Deep Brain Stimulation System for Psychiatric Disorders to Be Presented at International Neurosurgical Meeting
Devices Neurosurgery
 HSMN NewsFeed - 14 Apr 2008
Jazz Pharmaceuticals' LUVOX CR Is Now Available for Patients With Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Approves LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2007
FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Sep 2007
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Aug 2007
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Aug 2007
Noven Completes Acquisition of JDS Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2007
Jazz Pharmaceuticals, Inc. and Solvay Pharmaceuticals, Inc. Announce License Agreement for LUVOX(R) (Fluvoxamine Maleate) Tablets and Fluvoxamine Maleate Extended-Release Capsules in the United States
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Jan 2007
Cipralex Approved in Europe for the Treatment of Obsessive Compulsive Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Oct 2006
Dedicated TomoTherapy(R) Treatment Facility Sees Immediate Results
Devices Oncology
 HSMN NewsFeed - 10 Oct 2006
CardioVascular Technologies, Inc. Announces Patent Notice of Allowance for Its Sutureless Anastomosis Coupler Technology - System Enables Clampless Coronary Artery Bypass Graft (CABG) Surgery
Devices Cardiology
 HSMN NewsFeed - 21 Sep 2006
Telbivudine Approved in Switzerland for Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
OCD
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!